Sponsor message
Now new in the US - Dietary diformates Made in Germany Learn more

Acquisition of Huvepharma Cleared by EC

by 5m Editor
12 November 2010, at 12:42am

EU - The European Commission (EC) has cleared the acquisition of Huvepharma by Citigroup.

The EC has cleared the acquisition of joint control over Bulgarian Huvepharma by Citigroup Venture Capital International Investment G.P. Limited (of Jersey) and Advance Properties, a Bulgarian investment company.

Huvepharma is predominantly active in animal health and nutrition markets, but also manufactures active pharmaceutical ingredients (APIs) for human health products.

The transaction does not meet the turnover thresholds of the Merger Regulation but would have required notification in more than three Member States. The parties therefore requested a referral of the case to the Commission pursuant to Article 4(5) of the Merger Regulation. Since none of the Member States concerned objected to the referral, the transaction is deemed to have an EU dimension and has been notified to the Commission. The parties' activities do not overlap, and the vertical effects between Huvepharma's business in some API markets and the activities of Citgroup fund companies in certain pharmaceutical markets downstream are extremely limited.

Consequently, the Commission has granted clearance to the transaction.

Sponsored content
Our Formi products fulfil tomorrow’s requirements today.

Formi NDF and the 3rd Generation acidifier Formi 3G have been formulated to replace the need for in-feed antibiotics, by ensuring a strong antibacterial impact against Gram negative and Gram positive bacteria.

The Formi product line, based on Addcon’s patented diformate technology ensures optimal efficiency, highest growth rates and maximum safety, which are key requirements in animal production worldwide – and are now available in the USA.

Learn more